Anti-Neoplastic Agents Global Market Report 2024

Description

“Anti-Neoplastic Agents Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anti-neoplastic agents market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anti-neoplastic agents? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The anti-neoplastic agents market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Type: Alkylating Agents; Antimetabolites; Hormones And Antagonists; Miscellaneous
2) By Disease Type: Gastrointestinal Cancer; Prostate Cancer; Lung Cancer; Breast Cancer; Other Disease Types
3) By End User: Hospitals; Clinics; Cancer Rehabilitation Centers; Ambulatory Surgical Centers
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Bayer AG; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Anti-neoplastic agents refer to drugs that inhibit or destroy abnormal tissue growth, specifically targeting and combating cancerous cells in the body. They have a vital role in cancer treatment by disrupting the processes involved in tumor development and progression.

The main types of anti-neoplastic agents are alkylating agents, antimetabolites, hormones and antagonists and miscellaneous. Alkylating agents are a class of chemical compounds that can add alkyl groups to DNA, RNA and proteins, disrupting their normal function and interfering with cell replication. These are used to treat several diseases, including gastrointestinal cancer, prostate cancer, lung cancer, breast cancer and others and are used by various end users, such as hospitals, clinics, cancer rehabilitation centers and ambulatory surgical centers.

The anti-neoplastic agents market research report is one of a series of new reports from The Business Research Company that provides anti-neoplastic agents market statistics, including anti-neoplastic agent industry global market size, regional shares, competitors with an anti-neoplastic agent market share, detailed anti-neoplastic agents market segments, market trends and opportunities and any further data you may need to thrive in the anti-neoplastic agent industry. This anti-neoplastic agent market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anti-neoplastic agents market size has grown rapidly in recent years. It will grow from $118.03 billion in 2023 to $130.01 billion in 2024 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to increasing cancer incidence, growing demand for therapies, rising demand for minimally invasive cancer treatments, demand for affordable anti-neoplastic treatments.

The anti-neoplastic agents market size is expected to see strong growth in the next few years. It will grow to $184.17 billion in 2028 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to patient education and awareness, government initiative, growing demand for personalized cancer treatment, growing focus on quality of life in cancer treatment. Major trends in the forecast period include advancements in oncology research, development of targeted therapies, biotechnology innovation, advancements in diagnostic tools.

The growing incidence of cancer is projected to drive the expansion of the antineoplastic agent market in the future. Cancer encompasses a spectrum of diseases that can originate in almost any organ or tissue within the body, characterized by the uncontrolled proliferation of abnormal cells that breach their natural boundaries, potentially spreading to other organs or invading neighboring tissues. Antineoplastic agents assume a crucial role in cancer treatment by inhibiting the growth and division of cancerous cells through diverse mechanisms, including DNA damage, disruption of the cell cycle, and interference with vital cellular pathways. For example, in 2023, as reported by the American Cancer Society Inc., a nonprofit health organization based in the United States, it is estimated that there will be approximately 1.9 million new cancer cases diagnosed in the US, marking an increase from the 1.8 million cases identified in 2020. Moreover, it is anticipated that there will be 609,820 cancer-related deaths in 2023, compared to 606,520 in 2020. Consequently, the rising incidence of cancer is a significant driver of growth in the antineoplastic agent market.

The growth of the anti-neoplastic agent market is expected to be driven by an increase in investment in cancer research. This investment involves allocating financial resources to support scientific endeavors aimed at studying, preventing, diagnosing, and treating cancer. The additional funding for cancer research enables pharmaceutical and biotechnology companies to explore, develop, and rigorously test new anti-neoplastic agents, which includes identifying potential drug targets and creating candidate compounds. For example, in March 2022, the Australian Department of Health and Aged Care allocated $893.5 million to improve cancer services and outcomes. A portion of this investment, $329.4 million, is earmarked for new cancer drugs like Trodelvy, Lynparza, and Mylotarg, which can potentially benefit hundreds of patients annually. Consequently, the increased investment in cancer research is poised to drive the growth of the anti-neoplastic agent market.

The anti-neoplastic agents market could face significant hindrances in its growth due to the substantial expenses associated with these drugs. Developing neoplastic agents is a costly process, and the varied nature of cancer further contributes to these high costs. As an illustration, in May 2023, data from IQVIA Inc., a US-based company specializing in healthcare information technology and pharmaceutical clinical research, indicated that there has been an increase in the number of new cancer drugs with annual expenses exceeding $200,000. In the previous year, the expenditure on high-cost cancer therapies reached $48 billion, with the median yearly price for new oncology medications standing at $260,000. Hence, the exorbitant expenses of anti-neoplastic agents impede the growth of this market.

Leading companies in the field of anti-neoplastic agents are dedicated to the development of clinical practices to maintain their market position. For instance, in March 2022, Novartis AG, a pharmaceutical company headquartered in Switzerland, announced the approval of Pluvicto by the Food and Drug Administration (FDA). Pluvicto is the first targeted radioligand therapy approved for the treatment of progressive metastatic castration-resistant prostate cancer (mCRPC) that is positive for PSMA (Prostate-specific membrane antigen). The recommended treatment regimen involves administering 7.4 GBq (200 mCi) of Pluvicto intravenously every six weeks for a maximum of six doses, with treatment cessation upon disease progression or if intolerable toxicity occurs, whichever happens first. Patient selection for Pluvicto treatment in previously treated mCRPC should be based on the assessment of PSMA expression in tumors, employing Locametz or another authorized PSMA-11 imaging agent.

In August 2022, Ipsen SA, a biopharmaceutical company headquartered in France, completed the acquisition of Epizyme Inc. for a total of $247 million. This strategic move by Ipsen is intended to broaden its oncology portfolio by incorporating Tazverik, an innovative EZH2 inhibitor that offers a chemotherapy-free treatment option. Epizyme Inc., based in the United States, is a biopharmaceutical company known for its contributions in the field of anti-neoplastic agents.

Major players in the anti-neoplastic agents market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Ipsen SA, Cipla Limited, Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Gland Pharma Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Jubilant Life Sciences Ltd., Lantheus Holdings Inc., Hutchison Medipharma Ltd., Natco Pharma Ltd., Accord Healthcare Limited, Qilu Pharmaceutical Co. Ltd.

North America was the largest region in the anti-neoplastic agents market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-neoplastic agents report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the anti-neoplastic agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anti-neoplastic agents market consists of sales of antitumor antibiotics, microtubule inhibitors and topoisomerase inhibitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Product Code: r12247

1. Executive Summary

2. Anti-Neoplastic Agents Market Characteristics

3. Anti-Neoplastic Agents Market Trends And Strategies

4. Anti-Neoplastic Agents Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Anti-Neoplastic Agents Market Size and Growth

5.1. Global Anti-Neoplastic Agents Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Anti-Neoplastic Agents Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Anti-Neoplastic Agents Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Anti-Neoplastic Agents Market Segmentation

6.1. Global Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Alkylating Agents
Antimetabolites
Hormones And Antagonists
Miscellaneous
6.2. Global Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Gastrointestinal Cancer
Prostate Cancer
Lung Cancer
Breast Cancer
Other Disease Types
6.3. Global Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals
Clinics
Cancer Rehabilitation Centers
Ambulatory Surgical Centers

7. Anti-Neoplastic Agents Market Regional And Country Analysis

7.1. Global Anti-Neoplastic Agents Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Anti-Neoplastic Agents Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Anti-Neoplastic Agents Market

8.1. Asia-Pacific Anti-Neoplastic Agents Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Anti-Neoplastic Agents Market

9.1. China Anti-Neoplastic Agents Market Overview
9.2. China Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Anti-Neoplastic Agents Market

10.1. India Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Anti-Neoplastic Agents Market

11.1. Japan Anti-Neoplastic Agents Market Overview
11.2. Japan Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Anti-Neoplastic Agents Market

12.1. Australia Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Anti-Neoplastic Agents Market

13.1. Indonesia Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Anti-Neoplastic Agents Market

14.1. South Korea Anti-Neoplastic Agents Market Overview
14.2. South Korea Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Anti-Neoplastic Agents Market

15.1. Western Europe Anti-Neoplastic Agents Market Overview
15.2. Western Europe Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Anti-Neoplastic Agents Market

16.1. UK Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Anti-Neoplastic Agents Market

17.1. Germany Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Anti-Neoplastic Agents Market

18.1. France Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Anti-Neoplastic Agents Market

19.1. Italy Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Anti-Neoplastic Agents Market

20.1. Spain Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Anti-Neoplastic Agents Market

21.1. Eastern Europe Anti-Neoplastic Agents Market Overview
21.2. Eastern Europe Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Anti-Neoplastic Agents Market

22.1. Russia Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Anti-Neoplastic Agents Market

23.1. North America Anti-Neoplastic Agents Market Overview
23.2. North America Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Anti-Neoplastic Agents Market

24.1. USA Anti-Neoplastic Agents Market Overview
24.2. USA Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Anti-Neoplastic Agents Market

25.1. Canada Anti-Neoplastic Agents Market Overview
25.2. Canada Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Anti-Neoplastic Agents Market

26.1. South America Anti-Neoplastic Agents Market Overview
26.2. South America Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Anti-Neoplastic Agents Market

27.1. Brazil Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Anti-Neoplastic Agents Market

28.1. Middle East Anti-Neoplastic Agents Market Overview
28.2. Middle East Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Anti-Neoplastic Agents Market

29.1. Africa Anti-Neoplastic Agents Market Overview
29.2. Africa Anti-Neoplastic Agents Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Anti-Neoplastic Agents Market, Segmentation By Disease Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Anti-Neoplastic Agents Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Anti-Neoplastic Agents Market Competitive Landscape And Company Profiles

30.1. Anti-Neoplastic Agents Market Competitive Landscape
30.2. Anti-Neoplastic Agents Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. F. Hoffmann-La Roche Ltd.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Merck & Co. Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Bayer AG
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Novartis AG
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Anti-Neoplastic Agents Market Other Major And Innovative Companies

31.1. Bristol-Myers Squibb Company
31.2. AstraZeneca PLC
31.3. Fresenius SE & Co. KGaA
31.4. Takeda Pharmaceutical Company Limited
31.5. Boehringer Ingelheim International GmbH
31.6. Viatris Inc.
31.7. Teva Pharmaceutical Industries Ltd.
31.8. Eisai Co. Ltd.
31.9. Sun Pharmaceutical Industries Limited
31.10. Ipsen SA
31.11. Cipla Limited
31.12. Dr. Reddy's Laboratories Ltd.
31.13. Intas Pharmaceuticals Limited
31.14. Hikma Pharmaceuticals PLC
31.15. Gland Pharma Limited

32. Global Anti-Neoplastic Agents Market Competitive Benchmarking

33. Global Anti-Neoplastic Agents Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Anti-Neoplastic Agents Market

35. Anti-Neoplastic Agents Market Future Outlook and Potential Analysis

35.1 Anti-Neoplastic Agents Market In 2028 - Countries Offering Most New Opportunities
35.2 Anti-Neoplastic Agents Market In 2028 - Segments Offering Most New Opportunities
35.3 Anti-Neoplastic Agents Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer